|
|
|
|
Genzyme Plant Shutdown Could Mean up to $300M in Lost Sales
Sales of drugs for Fabry, Gauchers, and Pompe diseases will take a hit.Patricia F. Dimond, Ph. Genzymestands to lose between $100 million and $300 million in revenues related to Fabrazyme and Cerezyme as a result of the company...
|
|
|
Genyme Plant Shutdown Could Mean up to $300M in Lost Sales
Sales of drugs for Fabry, Gauchers, and Pompe disease will take a hit.Patricia F. Dimond, Ph. Genzymestands to lose between $100 million and $300 million in revenues related to Fabrazyme and Cerezyme as a result of the company...
|
|
|
Genzyme: The Next Big Biotech Machine
Genzyme (GENZ), which had a very broad range of treatment catering to numerous niche markets, is the company Im making reference to.This strategy was unprecedented until recently as the company targets those diseases that strike a very...
|
|
|
Genzyme Reports Progress Related to Allston Plant
- Genzyme Corporation (NASDAQ: GENZ) today provided an update on its progress toward restoring production at its Allston Landing manufacturing facility and in implementing temporary supply management measures.The company announced last...
|
|
|
Genzyme ships Gaucher's drug, offers update on plant closure
Genzyme Corp.said the company has begun shipping a finished batch of the Gauchers disease drug Cerezyme, after determining it was not contaminated by a virus that triggered a shut-down of the companys Allston, Mass. manufacturing...
|
|
|
Genzyme Reports Progress Related to Allston Plant
Genzyme Corporation has provided an update on its progress toward restoring production at its Allston Landing manufacturing facility and in implementing temporary supply management measures.The company recently announced that it had...
|
|
|
Protalix Initiates Home Care Treatment Program For Gaucher Patients
_ Protalix Initiates Home Care Treatment Program For Gaucher Patients.
|
|
|
Genzyme drugs could be rationed longer
Genzyme Corp.yesterday said supplies of two drugs that treat rare genetic disorders could be rationed for longer than originally thought. The extension is a result of an expanded cleanup effort at the biotechnology companys Boston...
|
|
|
Genzyme Resumes Shipping Of Cerezyme Stock
BOSTON -- Genzyme Corp.said Thursday that it has resumed shipping of finished lots of its flagship product Cerezyme from its Allston, Mass., plant after test showed the lots were free of a certain virus that resulted in the facility's...
|
|
|
Supply Shortages Of Cerezyme And Fabrazyme - Priority Access Forpatients Most In Need Of Treatment Recommended
The European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) has recommended that patients who are in greatest need of treatment are given priority access to Cerezyme (imiglucerase) and Fabrazyme (agalsidase...
|
|
|
Genzyme drugs could be rationed for longer
Genzyme Corp.yesterday said supplies of two drugs that treat rare genetic disorders could be rationed for longer than originally thought. The extension is a result of an expanded cleanup effort at the biotechnology companys Boston...
|
|
|
Drug maker begins cleanup to kill virus
A giant biotechnology firm has begun an intensive cleanup of a Boston plant to kill a virus that could infect drugs that treat genetic disorders, the firm says.Genzyme Corp., the world's third-largest biotechnology company, also received...
|
|
|
Virus pushes drug maker to halt production
A giant biotechnology firm has begun an intensive cleanup of a Boston plant to kill a virus that could infect drugs that treat genetic disorders, the firm says.Genzyme Corp., the world's third-largest biotechnology company, has dismantled...
|
|
|
::: Supply shortages of Cerezyme and Fabrazyme - priority access for patients most in need of treatment recomm
The European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) has recommended that patients who are in greatest need of treatment are given priority access to Cerezyme (imiglucerase) and Fabrazyme (agalsidase...
|
|
|
Protalix Initiates a Home Care Treatment Program for Gaucher Patients in the Phase III Extension Trial of prGC
- Protalix BioTherapeutics, Inc.(NYSE-AMEX:PLX), announced today the initiation of a home care treatment program for patients enrolled in the Companys phase III extension trial of plant-cell expressed recombinant glucocerebrosidase (prGCD...
|
|
|
Protalix Initiates a Home Care Treatment Program for Gaucher Patients in the Phase III Extension Trial of prGC
Protalix BioTherapeutics, Inc.(NYSE-AMEX:PLX), announced today the initiation of a home care treatment program for patients enrolled in the Companys phase III extension trial of plant-cell expressed recombinant glucocerebrosidase (prGCD),...
|
|
|
Genzyme ships Gaucher's drug, offers update on plant closure
Genzyme Corp.said the company has begun shipping a finished batch of the Gauchers disease drug Cerezyme, after determining it was not contaminated by a virus that triggered a shut-down of the companys Allston, Mass. manufacturing...
|
|
|
Protalix Initiates a Home Care Treatment Program for Gaucher Patients in the Phase III Extension Trial of prGC
The home care treatment program allows patients in the phase III extension trial to receive intravenous treatments of prGCD in the comfort of their own home, at a physician's discretion and under the supervision of a registered nurse.Upon...
|
|
|
Virus pushes drug maker to halt production
A giant biotechnology firm has begun an intensive cleanup of a Boston plant to kill a virus that could infect drugs that treat genetic disorders, the firm says.Genzyme Corp., the world's third-largest biotechnology company, has dismantled...
|
|
|
Europe prepares for shortages of Genzyme drug
Cancer Resources> Cancer News > Cancer News from Reuters > Reuters Cancer News > 2009 > June LONDON (Reuters) - Europe's drug watchdog has recommended a priority access system to deal with a shortage of two...
|
|
|
Genzyme Reports Progress Related to Allston Plant
- Genzyme Corporation (NASDAQ: GENZ) today provided an update on its progress toward restoring production at its Allston Landing manufacturing facility and in implementing temporary supply management measures.The company announced last...
|
|
|
Drug maker begins cleanup to kill virus
'giant biotechnology' search results Related Stories BOSTON, June 25 (UPI) -- A giant biotechnology firm has begun an intensive cleanup of a Boston plant to kill a virus that could infect drugs that treat genetic disorders, the firm says.
|
|
|
Genzyme confident Allston plant on line late July
NEW YORK, June 25 (Reuters) - Genzyme Corp said it was confident its Boston plant, shut down after a virus halted production of two of its top-selling drugs, would be back on line next month.The extensive disinfection process at the...
|
|
|
Virus pushes drug maker to halt production
'giant biotechnology' search results 'Boston plant' search results Related Stories BOSTON, June 25 (UPI) -- A giant biotechnology firm has begun an intensive cleanup of a Boston plant to kill a virus that could infect drugs that treat...
|
|
|
UPDATE 1-Europe prepares for shortages of Genzyme drugs
LONDON, June 25 (Reuters) - Europe's drug watchdog has recommended a priority access system to deal with a shortage of two top-selling drugs for rare diseases from Genzyme Corp.The U.S. company was forced to halt production of Cerezyme...
|
